References
- Murray RC, Chennupati SK. Chronic streptococcal and non-streptococcal pharyngitis. Infect Disord Drug Targets. 2012;12(4):281–285. doi:10.2174/18715261280131931122338589
- Bonsignori F, Chiappini E, De Martino M. The infections of the upper respiratory tract in children. Int J Immunopathol Pharmacol. 2010;23(Suppl 1):16–19.20152073
- Stelter K. Tonsillitis and sore throat in childhood. Laryngorhinootologie. 2014;93(Suppl 1):S84–S102. doi:10.1055/s-0033-136321024710788
- Douglas CM, Lang K, Whitmer WM, Wilson JA, Mackenzie K. The effect of tonsillectomy on the morbidity from recurrent tonsillitis. Clin Otolaryngol. 2017;42:1206–1210. doi:10.1111/coa.1285028199053
- El Hennawi DE, Rifaat Ahmed M. Quality of life after tonsillectomy versus azithromycin. Interv Med Appl Sci. 2016;8(4):141–146. doi:10.1556/1646.8.2016.4.228180002
- Wescombe PA, Hale JD, Heng NC, Tagg JR. Developing oral probi- otics from Streptococcus salivarius. Future Microbiol. 2012;7(12):1355–1371. doi:10.2217/fmb.12.11323231486
- Tagg JR. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med. 2004;119(Suppl):13–16.
- Hyink O, Wescombe PA, Upton M, Ragland N, Burton JP, Tagg JR. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol. 2007;73(4):1107–1113. doi:10.1128/AEM.02265-0617194838
- Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991–997. doi:10.2147/IJGM.S3885923233809
- Di Pierro F, Colombo M, Giuliani MG, et al. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children. Eur Rev Med Pharmacol Sci. 2016;20(21):4601–4606.27874935
- Gregori G, Righi O, Risso P, et al. Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag. 2016;12:87–92. doi:10.2147/TCRM.S9613426855579
- Di Pierro F, Di Pasquale D, Di Cicco M. Oral use of Streptococcus salivarius K12 in children with secretory otitis media: preliminary results of a pilot, uncontrolled study. Int J Gen Med. 2015;8:303–308. doi:10.2147/IJGM.S9248826396541
- Di Pierro F, Colombo M, Zanvit A, Risso P, Rottoli AS. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug Healthc Patient Saf. 2014;6:15–20. doi:10.2147/DHPS.S5966524600248
- Di Pierro F, Adami T, Rapacioli G, Giardini N, Streitberger C. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther. 2013;13(3):339–343. doi:10.1517/14712598.2013.7587123286823
- Reusser NM, Bender RW, Agrawal NA, Albright JT, Duncan NO, Edmonds JL. Post-tonsillectomy hemorrhage rates in children compared by surgical technique. Ear Nose Throat J. 2017;96(7):E7–E11. doi:10.1177/014556131709600702